Tolvaptan a novel oral vasopressin V2 receptor antagonist for the treatment of acute decompensated heart failure and hyponatremia

Formulary

Volumn 43, Issue 7, 2008, Pages 236-249

  Jennings, Douglas L ^a   Kalus, James S ^a  

^a HENRY FORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ARGIPRESSIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOBUTAMINE; FUROSEMIDE; GLYCERYL TRINITRATE; HYDRALAZINE; MILRINONE; NESIRITIDE; NITRATE; NITROPRUSSIDE SODIUM; PLACEBO; POTASSIUM; TOLVAPTAN;

ACUTE KIDNEY FAILURE; ANTIDIURESIS; AQUARESIS; ARTICLE; AUTOSOMAL DOMINANT DISORDER; BLOOD PRESSURE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CYANIDE TOXICITY; DIURESIS; DRUG APPROVAL; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG METABOLISM; DRUG SAFETY; DRUG WITHDRAWAL; ELECTROLYTE BLOOD LEVEL; ELECTROLYTE DISTURBANCE; ELECTROLYTE EXCRETION; FOOD AND DRUG ADMINISTRATION; HEADACHE; HEART ARRHYTHMIA; HEART FAILURE; HEART RATE; HEART RHYTHM; HUMAN; HYPERNATREMIA; HYPOKALEMIA; HYPONATREMIA; HYPOTENSION; INAPPROPRIATE VASOPRESSIN SECRETION; KIDNEY DISEASE; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KIDNEY FUNCTION; LIVER CIRRHOSIS; LIVER DISEASE; MORTALITY; NEUROENDOCRINE DISEASE; NONHUMAN; OVARY POLYCYSTIC DISEASE; POLYURIA; POTASSIUM BLOOD LEVEL; RECOMMENDED DRUG DOSE; SIDE EFFECT; THIOCYANATE TOXICITY; THIRST; TREATMENT DURATION; TREATMENT OUTCOME; WATER ABSORPTION; WEIGHT REDUCTION; XEROSTOMIA;

EID: 48249118855     PISSN: 1082801X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Rosamond W, Flegal K, Furie K, et al; for the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics 2008 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008;117:e25-e146.
2. O'Connell JB. The economic burden of heart failure. Clin Cardiol. 2000;23(suppl III):III6-III10.
3. Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K. Short-term risk of death after treatment with nesiritide for decompensated heart failure: A pooled analysis of randomized controlled trials. JAMA. 2005;293:1900-1905.
4. Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure [erratum in Circulation. 2005;111:2274]. Circulation. 2005;111:1487-1491.
5. Mebazaa A, Nieminen MS, Packer M, et al; for the SURVIVE Investigators. Levosimendan vs dobutamine for patients with acute decompensated heart failure: The SURVIVE Randomized Trial. JAMA. 2007;297:1883-1891.
6. Jackson EK. Vasopressin and other agents affecting the renal conservation of water. In: Goodman & Gilman's The Pharmacological Bash of Therapeutics. 11th ed. New York, NY: McGraw-Hill Companies Inc; 2006.
7. Goldsmith SR, Gheorghiade M. Vasopressin antagonism in heart failure. J Am Coll Cardiol. 2005;46:1785-1791.
8. Gassanov N, Jankowski M, Danalache B, et al. Arginine vasopressin-mediated cardiac differentiation. J Biol Chem. 2007;282:11255-11265.
9. Lee CR, Watkins ML, Patterson JH, et al. Vasopressin: A new target for the treatment of heart failure. Am Heart J. 2003;146:9-18.
10. 2-receptor antagonist: Pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther. 1998;287:860-867.
11. 2-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats. J Pharmacol Exp Ther. 2000;292:288-294.
12. Costello-Boerrigter LC, Smith WB, Boerrigter G, et al. Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Am J Physiol Renal Physiol. 2006;290:F273-F278.
13. 2-receptor antagonist - pharmacology and clinical trials. Cardiovasc Drug Rev. 2007;25:1-13.
14. Shoaf SE, Elizari MV, Wang Z, et al. Tolvaptan administration does not affect steady state amiodarone concentrations in patients with cardiac arrhythmias. J Cardiovasc Pharmacol Ther. 2005;10:165-171.
15. Otsuka Maryland Research Institute, Inc. granted fast track designation for toivaptan in PKD. Medical News Today. http://www.medicalnews today.com/articles/38392.php. Published February 25, 2006. Accessed June 11, 2008.
16. 2-receptor blockade with tolvaptan in patients with chronic heart failure: Results from a double-blind, randomized trial. Circulation. 2003;107:2690-2696.
17. Gheorghiade M, Gattis WA, O'Connor CM, et al; for the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure (ACTIV in CHF) Investigators. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: A randomized controlled trial. JAMA. 2004;291:1963-1971.
18. Gheorghiade M, Konstam MA, Burnett JC Jr, et al; for the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Toivaptan (EVEREST) Investigators. Short-term clinical effects of toivaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: The EVEREST Clinical Status Trials. JAMA. 2007;297:1332-1343.
19. Konstam MA, Gheorghiade M, Burnett JC Jr, et al; for the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Effects of oral toivaptan in patients hospitalized for worsening heart failure: The EVEREST Outcome Trial. JAMA. 2007;297:1319-1331.
20. 2-receptor antagonist, for hyponatremia. N Engl J Med. 2006;355:2099-2112.
21. ADPKD: Autosomal dominant polycystic kidney disease. Polycystic Kidney Disease Foundation website. http://www.pkdcure.org/aboutpkd/adpkd/ tabid/218/default.aspx. Accessed June 11, 2008.
22. Wang X, Gattone V II, Harris PC, Torres VE. Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat. J Am Soc Nephrol. 2005;16:846-851.
23. OAPI - Pipeline. Otsuka America Pharmaceutical, Inc. website. http://www.otsuka.com/oapi/ oapipipeline.asp. Accessed June 11, 2008.
24. Hauptman PJ, Zimmer C, Udelson J, et al. Comparison of two doses and dosing regimens of tolvaptan in congestive heart failure. J Cardiovasc Pharmacol. 2005;46:609-614.
25. Nieminen MS, Bohm M, Cowie MR, et al; ESC Committee for Practice Guidelines (CPG). Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: The Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J. 2005;26:384-416.